SOME NEW PHARMACOLOGIC OPTIONS FOR OPEN-ANGLE GLAUCOMA
Guenka I. Petrova*
ABSTRACT
Glaucoma is the second leading cause for irreversible bilateral blindness worldwide. Open-angle glaucoma is multifactorial chronic disease of the optic nerve, characterized by damage of the retinal ganglion cells and visual field impairment. Raised intraocular pressure is one of the strongest risk factors for development and progression of glaucoma and is the primary target of treatment. The aim of this review is to present the exiting pharmacological options for glaucoma therapy and to reveal new coming tendencies. The review is based on published information about the available and investigational pharmacological options for open angle glaucoma therapy. The articles
were retrieved through systematical search of PubMed, Google Scholar, Scopus. Currently six classes of drugs are used to treat glaucoma, acting by either decreasing aqueous humor production or by increasing aqueous outflow. New classes of drugs are being clinically tested: a novel compound with dual EP3 and FP agonist activity, ONO-9054 and Rho kinase inhibitors, like ripasudil (K-115). More efficient pharmacologic therapy for patients with primary open-angle glaucoma and ocular hypertension may be available soon.
Keywords: Open angle glaucoma, pharmacology therapy, Rho kinase inhibitors, prostaglandin analogues, dual EP3 and FP agonist activity, ONO-9054, like ripasudil (K-115).
[Download Article]
[Download Certifiate]